Prosaposin: A myelinotrophic protein that promotes expression of myelin constituents and is secreted after nerve injury

GLIA

Volumn 26, Issue 4, 1999, Pages 353-360

  Hiraiwa, Masao ^a   Campana, W Marie ^a   Mizisin, Andrew P ^b   Mohiuddin, Liza ^b   O'Brien, John S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Galactocerebroside; Myelin marker; Myelination; Nerve injury; Nerve regeneration; Neurotrophic factor; P0 protein; Saposin; Schwann cells; Sphingolipid activator protein; Sulfatide; UDP galactose:ceramide galactosyltransferase

Indexed keywords

GLYCOPROTEIN; NERVE GROWTH FACTOR; PROSAPTIDE; PSAP PROTEIN, HUMAN; PSAP PROTEIN, RAT; SOMATOMEDIN C; SPHINGOLIPID ACTIVATOR PROTEIN;

ANIMAL; ARTICLE; CELL CULTURE; CELL DIVISION; CYTOLOGY; DRUG EFFECT; ENZYME IMMUNOASSAY; HUMAN; INJURY; METABOLISM; MYELIN SHEATH; RAT; SCHWANN CELL; SCIATIC NERVE; SECRETION;

ANIMALS; CELL DIVISION; CELLS, CULTURED; GLYCOPROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; INSULIN-LIKE GROWTH FACTOR I; MYELIN SHEATH; NERVE GROWTH FACTORS; RATS; SAPOSINS; SCHWANN CELLS; SCIATIC NERVE;

EID: 0033152846     PISSN: 08941491     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1136(199906)26:4<353::AID-GLIA9>3.0.CO;2-G     Document Type: Article

References (33)

1. Bosio A, Binczek E, Stoffel W. 1996a. Functional breakdown of the lipid bilayer of the myelin membrane in central and peripheral nervous system by disrupted galactocerebroside synthesis. Proc Natl Acad Sci USA 93:13280-13285.
2. Bosio A, Binczek E, Stoffel W, 1996b. Molecular cloning and characterization of the mouse CGT gene encoding UDP-galactose ceramide-galactosyltransferase (ceramide synthetase). Genome 35:223-226.
3. Campana WM, Hiraiwa M, O'Brien JS. 1998. Prosaptide activates the mitogen-activated protein kinase pathway by a G-protein-dependent mechanism essential for enhanced sulfatide synthesis by Schwann cells. FASEB J 12:307-314.
4. Cheng L, Mudge AW. 1996. Cultured Schwann cells constitutively express the myelin protein PO. Neuron 16:309-319.
5. Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159.
6. Coetzee T, Fujita N, Dupree J, Shi R, Blight A, Suzuki K, Suzuki K, Popko B. 1996. Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell 86:209-219.
7. Costantino-Ceccarini E, Suzuki K. 1975. Effect of exogeneous lipids on membrane-bound ceramide glycosyltransferase of rat brain. Arch Biochem Biophys 167:646-654.
8. deF Webster, H. 1997. Growth factors and myelin regeneration in multiple sclerosis. Multiple Sclerosis 3:113-120.
9. Dupree JL, Coetzee T, Blight A, Suzuki K, Popko B. 1998. Myelin galactolipids are essential for proper node of Ranvier formation in the CNS. J Neurosci 18:1642-1649.
10. Fu Q, Carson GS, Hiraiwa M, Grafe M, Kishimoto Y, O'Brien JS. 1994. Occurrence of prosaposin as a neuronal surface membrane component. J Mol Neurosci 5:59-67.
11. Fujita N, Suzuki K, Vanier MT, Popko B, Maeda N, Klein A, Henseler M, Sandhoff K, Nakayasu H, Suzuki K. 1996. Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum Mol Genet 5:711-725.
12. Gillen C, Gleichmann M, Spreyer P, Muller HW. 1995. Differential expressed gene after peripheral nerve injury. J Neurosci Res 42:159-171.
13. Harzer, K, Paton BC, Poulos A, Kustermann-Kuhn B, Roggendorf W, Grisar T, Popp M. 1989. Sphingolipid activator deficiency in a 16-week old atypical Gaucher disease patient and his fetal sibling: biochemical signs of combined sphingolipidoses. Eur J Pediatr 149:31-39.
14. Hill HD, Straka JG. 1988. Protein Determination using bicinchoininc acid in the presence of sulfhydryl reagents. Anal Biochem 170:203-208.
15. Hiraiwa M, O'Brien JS, Kishimoto Y, Gladzicka M, Fluharty AL, Ginns EI, Martin BM. 1993. Isolation, characterization, and proteolysis of human prosaposin, the precursor of saposins (sphingolipid activator proteins). Arch Biochem Biophys 304:110-116.
16. Hiraiwa M, Taylor EM, Campana WM, Darin SJ, O'Brien JS. 1997a. Cell death prevention, MAP kinase stimulation, and enhanced sulfatide synthesis in Schwann cell and oligodendrocyte. Proc Natl Acad Sci USA 94:4778-4781.
17. Hiraiwa M, Campana WM, Martin BM, O'Brien JS. 1997b. Prosaposin receptor: evidence for a G-protein associated receptor. Biochem Biophys Res Commun 240:415-418.
18. Hiraiwa M, Martin BM, Kishimoto Y, Conner GE, Tsuji S, O'Brien JS. 1997c. Lysosomal proteolysis of prosaposin, precursor of saposins (sphingolipid activator proteins): its mechanism and inhibition by ganglioside. Arch Biochem Biophys 341:17-24.
19. Kishimoto Y, Hiraiwa M, O'Brien JS. 1992. Saposins: structure, function, distribution, and molecular genetics. J Lipid Res 33:1255-1267.
20. Kondoh K, Hineno T, Sano A, Kakimoto Y. 1991. Isolation and characterization of prosaposin from human milk. Biochem Biophys Res Commun 181:286-292.
21. Kotani Y, Matsuda S, Wen T-C, Sakanaka M, Tanaka J, Maeda N, Kondoh K, Ueno S, Sano, A. 1996a. Ahydrophilic peptide comprising 18 amino acid residues of the prosaposin sequence has neurotrophic activity in vitro and in vivo. J Neurochem 66:2197-2200.
22. Kotani Y, Matsuda S, Sakanaka M, Kondoh K, Ueno S, Sano A. 1996b. Prosaposin facilitates sciatic nerve regeneration in vivo. J Neurochem 66:2019-2025.
23. Lemke G, Axel R. 1985. Isolation and sequence of a cDNA encoding the major structural protein of peripheral myelin. Cell 40:501-508.
24. Mahmoudi M, Lin VK 1989. Comparison of two different hybridization systems in Northern transfer analysis. Biotechniques 7:331-334.
25. O'Brien JS. 1965. Stability of the myelin membrane. Science 147:1099-1107.
26. O'Brien JS, Kishimoto Y. 1991. Saposin proteins: structure, function, and role in human lysosomal storage disorders. FASEB J 5:301-308.
27. O'Brien JS, Carson GS, Seo H-C, Hiraiwa M, Kishimoto Y. 1994. Identification of prosaposin as a neurotrophic factor. Proc Natl Acad Sci USA 91:9593-9596.
28. O'Brien JS, Carson GS, Seo H-C, Hiraiwa M, Weiler S, Tomich JA, Barranger JA, Kahn M, Azuma N, Kishimoto Y. 1995. Identification of the neurotrophic factor sequence of prosaposin. FASEB J 9:681-685.
29. Podhajsky RJ, Myers RR. 1994. The vascular response to nerve transection: neovascularization in the silicone nerve regeneration chamber. Brain Res 662:88-94.
30. Sandhoff K, Harzer K, Furst W. 1995. Sphingolipid activator proteins. In: Seriber CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill. p 2427-2441.
31. Sano A, Matsuda S, Wen T-C, Kotani Y, Kondoh K, Ueno S, Kakimoto Y, Yoshimura H, Sakanaka M. 1994. Protection by prosaposin against ischemia-induced learning disability and neuronal loss. Biochem Biophys Res Commun 204:994-1000.
32. Schnabel D, Schroder M, Furst W, Hein A, Hurwitz R, Zenk T, Weber J, Harzer K, Paton BC, Poulos A, Suzuki K, Sandhoff K. 1992. Simultaneous deficiency of sphingplipid activator proteins 1 and 2 is caused by a mutation in the intiation codon of their common gene. J Biol Chem 267:3312-3315.
33. Stewart HJS, Bradke F, Taberno A, Morrel D, Jessen KR, Mirsky R. 1996. Regulation of rat Schwann cell P0 expression and DNA synthesis by insulin-like growth factors in vitro. Eur J Neurosci 8:553-564.